Brisbane, Australia, 16 June 2020 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, and Phenix Health Pty Ltd, Australia’s leading virtual super clinic, have signed a software licensing agreement to use ResApp’s acute respiratory diagnostic test, ResAppDx-EU, in Phenix’s telehealth smartphone app. ResAppDx-EU is approved by the Therapeutics Goods Administration (TGA) in Australia and is CE Marked in Europe as an aid for clinicians in the diagnosis of a range of respiratory diseases.
The two-year, non-exclusive commercial software licensing agreement allows Phenix to use ResAppDx-EU in their telehealth smartphone app within Australia from 1 July 2020. The per test license fee received by ResApp is in the previously targeted range of $5 to $10. The licence may be extended beyond the initial two-year term by mutual agreement and either party may terminate the licence by providing 60 days written notice.
“At Phenix we are establishing a first-of-its-kind virtual respiratory clinic to address the increasing demand we are seeing for remote acute respiratory disease care. We are excited to be launching ResAppDx-EU on our platform on the 1st of July,” said Dr Gillian Alexis, CEO and founder of Phenix Health. “Phenix is Australia’s leading virtual super clinic, delivering continuity of care, with over 300 general practitioners and specialists providing telehealth services Australia-wide. Tools such as ResAppDx-EU will allow our doctors to provide the highest levels of care to our patients in the virtual setting.”
Tony Keating, CEO and Managing Director of ResApp, added, “We are pleased to have partnered with Phenix to integrate ResAppDx-EU into their virtual super clinic. Our initial launch, via Phenix’s telehealth iOS application, will see our clinically-validated and regulatory-approved diagnostic test available to Phenix’s customers Australia-wide, empowering their doctors to better assess patients presenting with respiratory symptoms such as sore throat, runny nose, shortness-of-breath or cough.”
About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp’s regulatory-approved and clinically-validated products include ResAppDx-EU, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, an at-home sleep apnoea screening app for consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.
About Phenix Health Pty Ltd
Phenix Health Pty Ltd is an integrative medical tech company founded in 2015 as a spin-off from our Australia-wide after-hours home visit doctor service where it was evidenced that large sectors of the population were not able to access adequate healthcare services. Phenix worked towards developing and refining our mobile technology, remote patient monitoring and telehealth service that assists connect both health professionals to their patient. Our mobile technology includes many clinical operational features providing a powerful collaborative tool for health care providers in: clinic, aged care facilities, emergency services, hospitals and remote and mobile settings. Phenix Health solves the disconnect between vertical digital health silos. Our team has come together through years of experience in developing and operating 24/7 health care services across metro and regional. For more information, please visit www.phenixhealth.com.au.
Contacts for ResApp Health
Dr Tony Keating
CEO and Managing Director
+61 430 180 659
VP, Corporate Affairs
+61 412 281 780
ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St, Brisbane, QLD 4000
© 2020 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries. ResAppDx is not available for sale in the United States.